M&A Deal Summary

Bausch Health Acquires Synergetics USA

On October 15, 2015, Bausch Health acquired medical products company Synergetics USA

Acquisition Highlights
  • This is Bausch Health’s 6th transaction in the Medical Products sector.
  • This is Bausch Health’s 20th transaction in the United States.
  • This is Bausch Health’s 1st transaction in Montana.

M&A Deal Summary
Date 2015-10-15
Target Synergetics USA
Sector Medical Products
Buyer(s) Bausch Health
Deal Type Add-on Acquisition
Advisor(s) William Blair (Financial)
Armstrong Teasdale (Legal)

Target

Synergetics USA

O’Fallon, Montana, United States
Synergetics USA, Inc. is a provider fo precision surgical devices.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bausch Health

Laval, Quebec, Canada
Category Company
Sector Life Science
Employees20,270
Revenue 8.8B USD (2023)
DESCRIPTION

Bausch Health is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology, and branded generics. Bausch Health is based in Laval, Quebec.

DEAL STATS #
Overall 33 of 35
Sector (Medical Products) 6 of 6
Type (Add-on Acquisition) 25 of 25
State (Montana) 1 of 1
Country (United States) 20 of 22
Year (2015) 6 of 6
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-08-20 Sprout Pharmaceuticals

Raleigh, North Carolina, United States

Sprout Pharmaceuticals, Inc. is a life science company focused on women's sexual health. Sprout is passionate about women's sexual health and has focused solely on the delivery of a treatment option for the unmet need of premenopausal women with acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.

Buy $1.0B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-09 Dendreon Pharmaceuticals  

Seattle, Washington, United States

Dendreon Pharmaceuticals, Inc. is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.

Sell $820M
Mergr

Product

Company

Legal